These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 28398294)
1. Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study. Shih HJ; Kao MC; Tsai PS; Fan YC; Huang CJ Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):328-333. PubMed ID: 28398294 [TBL] [Abstract][Full Text] [Related]
2. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort. Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):483-490. PubMed ID: 30696944 [TBL] [Abstract][Full Text] [Related]
3. Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment. Vargas-Santos AB; Peloquin CE; Zhang Y; Neogi T JAMA Intern Med; 2018 Nov; 178(11):1526-1533. PubMed ID: 30304329 [TBL] [Abstract][Full Text] [Related]
4. Allopurinol and the incidence of bladder cancer: a Taiwan national retrospective cohort study. Chen CJ; Hsieh MC; Liao WT; Chan YT; Chang SJ Eur J Cancer Prev; 2016 May; 25(3):216-23. PubMed ID: 25830898 [TBL] [Abstract][Full Text] [Related]
5. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):373-378. PubMed ID: 29273728 [TBL] [Abstract][Full Text] [Related]
6. Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. Singh JA; Ramachandaran R; Yu S; Curtis JR BMC Cardiovasc Disord; 2017 Mar; 17(1):76. PubMed ID: 28288564 [TBL] [Abstract][Full Text] [Related]
7. Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus. Chang HW; Lin YW; Lin MH; Lan YC; Wang RY PLoS One; 2019; 14(1):e0210085. PubMed ID: 30615649 [TBL] [Abstract][Full Text] [Related]
8. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study. Kang EH; Choi HK; Shin A; Lee YJ; Lee EB; Song YW; Kim SC Rheumatology (Oxford); 2019 Dec; 58(12):2122-2129. PubMed ID: 31098635 [TBL] [Abstract][Full Text] [Related]
9. Risk of urolithiasis associated with allopurinol versus benzbromarone among patients with gout: a population-based cohort study. Kang EH; Shin A; Park CS; Lee EB; Lee YJ; Curhan G; Choi HK Rheumatology (Oxford); 2024 Sep; 63(9):2433-2441. PubMed ID: 38733596 [TBL] [Abstract][Full Text] [Related]
10. Increased risk of cancer among gout patients: a nationwide population study. Kuo CF; Luo SF; See LC; Chou IJ; Fang YF; Yu KH Joint Bone Spine; 2012 Jul; 79(4):375-8. PubMed ID: 22088929 [TBL] [Abstract][Full Text] [Related]
11. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study. Kok VC; Horng JT; Chang WS; Hong YF; Chang TH PLoS One; 2014; 9(6):e99102. PubMed ID: 24897240 [TBL] [Abstract][Full Text] [Related]
12. Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study. Su CY; Shen LJ; Hsieh SC; Lin LY; Lin FJ Mayo Clin Proc; 2019 Jul; 94(7):1147-1157. PubMed ID: 31272565 [TBL] [Abstract][Full Text] [Related]
13. Gout, allopurinol use, and heart failure outcomes. Thanassoulis G; Brophy JM; Richard H; Pilote L Arch Intern Med; 2010 Aug; 170(15):1358-64. PubMed ID: 20696962 [TBL] [Abstract][Full Text] [Related]
14. Allopurinol Dose Escalation and Mortality Among Patients With Gout: A National Propensity-Matched Cohort Study. Coburn BW; Michaud K; Bergman DA; Mikuls TR Arthritis Rheumatol; 2018 Aug; 70(8):1298-1307. PubMed ID: 29513934 [TBL] [Abstract][Full Text] [Related]
15. Adherence and persistence to urate-lowering therapies in the Irish setting. McGowan B; Bennett K; Silke C; Whelan B Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858 [TBL] [Abstract][Full Text] [Related]
16. Association of gout and colorectal cancer in Taiwan: a nationwide population-based cohort study. Chuang JP; Lee JC; Leu TH; Hidajah AC; Chang YH; Li CY BMJ Open; 2019 Oct; 9(10):e028892. PubMed ID: 31601586 [TBL] [Abstract][Full Text] [Related]
17. Effect of allopurinol on all-cause mortality in adults with incident gout: propensity score-matched landmark analysis. Kuo CF; Grainge MJ; Mallen C; Zhang W; Doherty M Rheumatology (Oxford); 2015 Dec; 54(12):2145-50. PubMed ID: 26170376 [TBL] [Abstract][Full Text] [Related]
18. Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study. Lin HC; Daimon M; Wang CH; Ho Y; Uang YS; Chiang SJ; Wang LH Int J Cardiol; 2017 Apr; 233():85-90. PubMed ID: 28202260 [TBL] [Abstract][Full Text] [Related]
19. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. Hill EM; Sky K; Sit M; Collamer A; Higgs J J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090 [TBL] [Abstract][Full Text] [Related]
20. Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). Scheepers LEJM; Burden AM; Arts ICW; Spaetgens B; Souverein P; de Vries F; Boonen A Rheumatology (Oxford); 2018 Sep; 57(9):1641-1650. PubMed ID: 29893941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]